fludarabine has been researched along with Anemia in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (20.00) | 18.2507 |
2000's | 7 (46.67) | 29.6817 |
2010's | 4 (26.67) | 24.3611 |
2020's | 1 (6.67) | 2.80 |
Authors | Studies |
---|---|
Cao, J; Cheng, H; Gao, X; Jiao, J; Li, D; Li, W; Li, Z; Liu, H; Ma, Y; Qin, Y; Sang, T; Sang, W; Shi, M; Song, X; Sun, C; Sun, H; Sun, K; Wang, Y; Wu, M; Xu, K; Xu, L; Yan, D; Yan, Z; Yang, J; Yao, M; Zeng, L; Zhang, B; Zheng, J; Zhu, F | 1 |
Austin, E; Burt, DJ; Byatte, AJ; Chester, KA; Gilham, DE; Guest, RD; Halford, SER; Hawkins, RE; Kirillova, N; Nabarro, S; Pillai, M; Rothwell, DG; Sharma, SK; Thistlethwaite, FC; Valle, JW; Wan, S; Westwood, NB | 1 |
Chiusolo, P; De Padua, L; Efremov, DG; Garzia, M; Innocenti, I; Laurenti, L; Leone, G; Piccirillo, N; Sica, S; Sorà, F; Tarnani, M; Zini, G | 1 |
Alessandro, A; Allegra, A; Alonci, A; Bellomo, G; Caterina, M; D'Angelo, A; Granata, A; Quartarone, E; Rizzotti, P | 1 |
Carney, D; Gill, S; Januszewicz, H; Prince, HM; Ritchie, D; Seymour, JF; Westerman, D; Wolf, M | 1 |
Atkins, JN; Bengtson, EM; Byrd, JC; Donohue, KA; Hoke, EE; Larson, RA; Lin, TS; Link, BK; Lucas, MS; Rai, KR | 1 |
Baldini, L; Federico, M; Ferrario, A; Goldaniga, MC; Luminari, S; Mannina, D; Marcheselli, L; Mazza, P; Merli, F; Russo, M; Stelitano, C | 1 |
Eagleton, H; Hatton, C; Leyden, K; Littlewood, T; Pearson, D; Pillai, N; Sternberg, A; Turner, S | 1 |
Hartmann, JT; Kanz, L; Klingel, K; Kröber, SM; Meisinger, I; Weisel, K | 1 |
Brugiatelli, M; Federico, M; Liberati, M; Marcheselli, R; Merli, F; Orsucci, L; Pozzi, S; Sacchi, S; Tucci, A; Vallisa, D | 1 |
Lundberg, JH; Tefferi, A; Weitz, JJ; Witzig, TE | 1 |
Doorduijn, JK; Michiels, JJ | 1 |
Cortes, J; Giles, F; Kantarjian, H; Keating, M; Koller, C; Loscertales, J; O'Brien, S; Thomas, D | 1 |
Diehl, V; Voliotis, D | 1 |
Bladé, J; Cervantes, F; Marín, P; Montserrat, E; Rozman, C; Rozman, M | 1 |
2 review(s) available for fludarabine and Anemia
Article | Year |
---|---|
Challenges in treating hematologic malignancies.
Topics: Anemia; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epoetin Alfa; Erythropoietin; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Prognosis; Quality of Life; Recombinant Proteins; Vidarabine | 2002 |
[Treatment with cyclosporin A of the anemia associated with chronic lymphatic leukemia].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclosporins; Erythropoiesis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Red-Cell Aplasia, Pure; T-Lymphocytes, Regulatory; Thrombocytopenia; Vidarabine | 1990 |
7 trial(s) available for fludarabine and Anemia
Article | Year |
---|---|
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 Ratio; Confidence Intervals; Cyclophosphamide; Cytokine Release Syndrome; Female; Glycolysis; Humans; Ifosfamide; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Progression-Free Survival; Receptors, Chimeric Antigen; Recurrence; T-Lymphocytes; Thrombocytopenia; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Topics: Abdominal Pain; Adult; Aged; Anemia; Carcinoembryonic Antigen; Cohort Studies; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Immunotherapy, Adoptive; Interferon-gamma; Interleukin-6; Lung; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Receptors, Antigen, T-Cell; T-Lymphocytes; Treatment Outcome; Vidarabine; Vomiting | 2017 |
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Topics: Administration, Oral; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neutropenia; Remission Induction; Vidarabine | 2008 |
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neoplasm, Residual; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Italy; Lymphoma, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine; Young Adult | 2011 |
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gene Rearrangement; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thrombocytopenia; Time Factors; Treatment Outcome; Vidarabine | 2007 |
Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.
Topics: Aged; Anemia; Antineoplastic Agents; Cyclosporine; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Splenectomy; Thrombocytopenia; Vidarabine | 2001 |
6 other study(ies) available for fludarabine and Anemia
Article | Year |
---|---|
Fludarabine based treatment caused improvement of anemia in a patient with T-cell LGL leukemia despite evidence of the persistence of the abnormal T-cell clone.
Topics: Aged; Anemia; Clone Cells; Female; Humans; Leukemia, T-Cell; Treatment Outcome; Vidarabine | 2008 |
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Pancytopenia; Prevalence; Retrospective Studies; Thrombocytopenia; Time Factors; Vidarabine | 2010 |
Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Leukemia, T-Cell; Male; Middle Aged; Neutropenia; Vidarabine | 2003 |
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma.
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Immunotherapy; Leukopenia; Lymphoma, Follicular; Middle Aged; Parvoviridae Infections; Parvovirus B19, Human; Prednisolone; Recurrence; Rituximab; Vidarabine; Vincristine; Viremia | 2006 |
Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.
Topics: 2-Chloroadenosine; Anemia; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Deoxyadenosines; Fatal Outcome; Female; Humans; Immunophenotyping; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Male; Methotrexate; Middle Aged; Neoplastic Stem Cells; Prednisone; Salvage Therapy; Vidarabine; Vincristine; Zidovudine | 1994 |
Effectiveness of fludarabine in end-stage prolymphocytic leukemia.
Topics: Aged; Anemia; Antigens, CD; Antineoplastic Agents; Blood Transfusion; Chlorambucil; Female; Humans; Immunophenotyping; Leukemia, Prolymphocytic; Neoplasm Staging; Splenectomy; Thrombocytopenia; Vidarabine | 1994 |